#J_Clin_Oncol IF:42.1
Phase III RCT (n=402). Ramucirumab + irinotecan vs irinotecan in ramucirumab-refractory advanced gastric cancer (AGC) showed no OS benefit (HR 0.91, P=0.49) but improved PFS (HR 0.72, P=0.002). (RINDBeRG trial)
PMID:40408613
https://t.co/4KJ3tbg3rL
#ESMO24
KEYNOTE-811: pembrolizumab + trastuzumab and chemotherapy for HER2+ metastatic G/GEJ adenocarcinoma: Final overall survival
mFU: 50.2 mo
mOS➡️20.0 vs 16.8 mo
PD-L1 CPS ≥1➡️20.1 vs 15.7 mo
Presented by @sara_lonardi1